Role of metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) receptor agonists, and orlistat based multidrug therapy in glycemic control, weight loss, and euglycemia in diabesity: A real-world experience

Role of metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) receptor agonists, and orlistat based multidrug therapy in glycemic control, weight loss, and euglycemia in diabesity: A real-world experience

Background: This study evaluated the real-world weight loss and glycemic outcomes of multidrug therapy (MDT) according to various combinations of metformin, sodium-glucose cotransporter -2 inhibitor (SGLT2i), glucagon-like peptide-1 receptor analogs (GLP1a), and orlistat in diabesity. Methods: Data...

Full description

Bibliographic Details
Main Authors: Deep Dutta, Ritu Jaisani, Deepak Khandelwal, Soumitra Ghosh, Rajiv Malhotra, Sanjay Kalra
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Indian Journal of Endocrinology and Metabolism
Subjects:
Diabesity
diabetes reversal
GLP1 receptor agonists
metformin
orlistat
SGLT2 inhibitors
weight loss
Online Access:http://www.ijem.in/article.asp?issn=2230-8210;year=2019;volume=23;issue=4;spage=460;epage=467;aulast=Dutta

Internet

http://www.ijem.in/article.asp?issn=2230-8210;year=2019;volume=23;issue=4;spage=460;epage=467;aulast=Dutta

Similar Items